Back to Archived News
Medistem Files Patent Application on Therapeutic Cell Population Found in Fat Tissue
Monday, January 21, 2008
Recent Findings Indicate Novel Means of Controlling Autoimmunity and Transplant Rejection
Medistem Laboratories, Inc. (OTCBB: MDSM) (FRANKFURT: S2U) has filed a patent application covering recent findings documenting the existence of high concentrations of therapeutic anti-inflammatory cells, called T regulatory cells, in fat tissue. The findings, confirmed by Medistem collaborator Dr. Hao Wang at the Lawson Health Research Institute, London, Canada, supports the possibility that the therapeutic effects previously observed by other groups using fat stem cells may be not be strictly due to the stem cells in the fat tissue but to the T regulatory cell population.
"The patent application covers not only methods of using fat tissue for suppressing inflammatory and autoimmunity, but also methods of expanding and increasing activity of these therapeutic cells," said Neil Riordan PhD, President and CEO of Medistem. He continued, "The current findings support development of therapeutics that suppress diseases with the body's own natural means, avoiding the need for toxic non-specific immune suppressants and steroids. If treatments can be developed based on these findings, patients could rely on T regulatory cells found in their own fat tissue, instead of non-specific drugs."
Medistem is currently working with several academic collaborators to develop regenerative and immune modulatory therapeutics using cellular populations derived from the fat tissue, cord blood, and as recently published, menstrual blood.
"Autoimmune diseases affect approximately 5-8 percent of the American population, being the 3rd major cause of illness behind cancer and heart disease. We are confident that our findings and intellectual property positioning in this area may enable Medistem to start addressing a substantially relevant unmet need," concluded Chris McGuinn, COO of Medistem.
About Medistem Laboratories, Inc.
Medistem Laboratories is a biotechnology company that discovers, develops, and commercializes adult stem cell products that address serious medical conditions. While drug discovery and development is its primary focus, Medistem has compiled a body of proprietary technologies it outlicenses to commercial entities in markets where stem cell administration is permissible. Due to its licensee relationships and collaborative efforts with respected institutions, Medistem believes it is well positioned to be a leading developer of adult stem cell products.
This document does not constitute an offer to sell or a solicitation of an offer to buy any of our securities. This document contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may include projections of matters that affect revenue, the ability to develop or license certain technologies and receive associated licensing fees; operating expenses or net earnings; projections of capital expenditures; projections of growth; hiring plans; plans for future operations; financing needs or plans; plans relating to the company's products and services; and assumptions relating to the foregoing.
Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking information.
Some of the important factors that could cause the company's actual results to differ materially from those projected in forward-looking statements made by the company include, but are not limited to, the following: the company's ability to anticipate future license fees, technology development limitations, intense competition, risk of business interruption, management of rapid growth, need for additional financing, regulatory approvals and requirements, dependence on key personnel and research, management and other administrative costs.
These factors are discussed in greater detail in the company's quarterly and annual periodic reports, all as filed with the Securities and Exchange Commission.
Back to Archived News